The increasing prevalence of glaucoma worldwide, along with the growing geriatric population that is more susceptible to the disease, is driving the growth of the glaucoma market. Additionally, advancements in technology and research leading to the development of innovative treatment options are creating opportunities for market growth. Furthermore, the rising awareness about the importance of early detection and management of glaucoma is also contributing to the expansion of the market.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Type, Drug Class, Distribution Channel |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Pfizer, Santen Pharmaceutical, Novartis AG, Alcon, Akron Operating Company LLC, Thea Pharma, AbbVie,, Bausch + Lomb, Teva Pharmaceuticals Industries. |
The high cost associated with the diagnosis and treatment of glaucoma acts as a major restraint for market growth. Additionally, the lack of access to healthcare facilities, especially in rural and underdeveloped regions, limits the reach of glaucoma treatment options. These restraints pose challenges in addressing the unmet needs of patients and hinder the overall growth potential of the glaucoma market.